Pharmacokinetic assessment of ketanserin in the horse
Article first published online: 18 NOV 2011
© 2011 Blackwell Publishing Ltd
Journal of Veterinary Pharmacology and Therapeutics
Volume 35, Issue 5, pages 472–477, October 2012
How to Cite
ALJUFFALI, I. A., BRAINARD, B. M., MOORE, J. N., KWON, S., ALLEN, D., ROBERTSON, T. P. and ARNOLD, R. D. (2012), Pharmacokinetic assessment of ketanserin in the horse. Journal of Veterinary Pharmacology and Therapeutics, 35: 472–477. doi: 10.1111/j.1365-2885.2011.01346.x
- Issue published online: 11 SEP 2012
- Article first published online: 18 NOV 2011
- (Paper received 6 May 2011; accepted for publication 17 October 2011)
Aljuffali, I. A., Brainard, B. M., Moore, J. N., Kwon, S., Allen, D., Robertson, T. P., Arnold, R. D. Pharmacokinetic assessment of ketanserin in the horse. J. vet. Pharmacol. Therap. 35, 472–477.
The purpose of this study was to determine the pharmacokinetics (PK) of the 5-HT2A receptor antagonist ketanserin in healthy adult horses, and to develop a computational model that could be used to optimize dosing. Plasma concentrations of ketanserin were determined using liquid chromatography with mass spectrometry after single and multiple intravenous administration in the horse. A two-compartment linear pharmacokinetic model described the plasma concentration–time profile of ketanserin after single and multiple doses in healthy horses; the terminal half-life was 11.5 h; steady-state volume of distribution was 10.5 L/kg; AUC was 115 ng·h/mL; and clearance was 0.87 L/h/kg. Model simulations followed by the examination in three healthy horses suggest 0.3 mg/kg q.8 h exhibited linear PK and produced consistent systemic blood concentrations of ketanserin above 3 ng/mL.